Bookmark Icon
Print Icon
Email Icon
Physician HeadShot

Cheryl H. Waters, MD

Neurology (Board Certified, Primary Specialty)
Office Phone: (212) 305-1303, (914) 366-4200
One of America's Top Doctors
Rated one of New York Magazine's Best Doctors


Cheryl Waters MD FRCP(C), holds bachelors and masters degrees in Pharmacology from the University of Toronto, where she studied dopamine receptor function with Philip Seeman. She completed medical school at University of Toronto, an internship at University of Chicago, and returned to Toronto for Internal Medicine, Neurology and a fellowship in Clinical Pharmacology. She moved to California and developed the Movement Disorder Program at the University of Southern California. Dr. Waters then moved to New York to take on her current position as Chief of Clinical Practice and Services in the Division of Movement Disorders. She has been involved in research on the genetics of Parkinson's disease and the treatment of this disorder. She has authored numerous articles and book chapters and a book in its seventh edition: Diagnosis and Management of Parkinson's Disease. She has been an investigator in numerous studies involving a variety of new medical and surgical treatments. She is the first to hold the Albert B. and Judith L. Glickman Chair in Neurology.

Area of Expertise

Please contact the doctor's office to verify that your insurance is accepted.

Aetna [EPO, HMO, Medicare Managed Care, NY Signature, POS, PPO, Signature Administrators, Student Health]

Affinity [Essential Plan, Medicaid Managed Care, Medicare Managed Care]

Amida Care [Special Needs Plan]

Cigna [EPO, Great West, HMO, POS, PPO]

Empire Blue Cross Blue Shield [Blue Priority, EPO, HMO, Medicare (Mediblue), NYP Employee Plan, Pathway (Exchange), POS, PPO]

Empire Blue Cross Blue Shield HealthPlus [Child/Family Health Plus, Essential Plan, Medicaid Managed Care]

Fidelis Care [Child/Family Health Plus, Medicaid Managed Care, Medicare Managed Care]

Healthfirst [Child/Family Health Plus, Medicaid Managed Care, Medicare Managed Care]

Local 1199 [Local 1199]

MagnaCare [MagnaCare]

Medicare [Traditional Medicare (NY)]

Oxford Health Plans [Freedom, Liberty, Medicare Managed Care]

UnitedHealthcare [Columbia University Employee Plan, EPO, Essential Plan, HMO, Medicaid (Community Plan), Medicare Managed Care, POS, PPO]

VNSNY CHOICE [Medicare Managed Care, SelectHealth]

WellCare [Medicaid Managed Care, Medicare Managed Care]


University of Toronto Faculty of Medicine

Residency: University of Toronto Hospitals

Fellowship: University of Toronto Hospitals


Espay AJ,  Pagan FL, MD,Walter BL, MD; Morgan JC,  Elmer LW,. Waters CH,et al. Optimizing extended-release carbidopa/levodopa  in Parkinson’s disease: Consensus on conversion from standard therapy. Neurology Clinical Practice 2017;7:1-8

Chan RB, Perotte AJ, Zhou B, Liong C, Shorr EJ, Marder KS, Kang UJ, Waters CH, Levy OA, Xu Y, Shim HB. Elevated GM3 plasma concentration in idiopathic Parkinson’s disease: A lipidomic analysis. PloS one. 2017 Feb 17;12(2):e0172348.

Sklerov, M; Waters, C. Understanding Multiple System Atrophy: Could Genetics Lead the Way? US Neurology, 2016;12(2):110–2.

Alcalay R.N, Levy OA, Wolf P, Oliva P, Zhang, X.K, Waters,CH, et al. (2016). SCARB2 variants and glucocerebrosidase activity in Parkinson’s disease. npj Parkinson's Disease, 2, 16004.

Alcalay RN,  Levy OA, Waters CH et al, Glucocerebrosidase activity in Parkinson’s disease with and without GBA mutations. Brain Jun 2015, DOI: 10.1093/brain/awv179

Waters CH,  Nausieda P,  Dzyak L, et al, Long-Term Treatment with Extended-Release Carbidopa–Levodopa (IPX066) in Early and Advanced Parkinson’s Disease: A 9-Month Open-Label Extension Trial. CNS Drugs 2015:29:4: 341-350.

Gan-Or Z,   Alcalay RN, Bar-Shira A, Leblond C, Postuma RB,Ben-Shachar S, Waters C, et al. Genetic markers of Restless Legs Syndrome in Parkinson Disease. Park Related Disords

Sharp ME , Caccappolo E , Mejia-Santana H , Tang M –X , Rosado L , Orbe Reilly M , Ruiz D , Louis ED , Comella C,  Nance M , Bressman S , Scott WK , Tanner C  , Mickel , Waters C et al The relationship between Obsessive-Compulsive symptoms and PARKIN genotype: The CORE-PD study Mov Disord. 2015 Feb;30(2):278-83. doi: 10.1002/mds.26065

Waters, Cheryl H:  Diagnosis and Management of Parkinson's Disease.  Professional Communications Inc., Caddo, Oklahoma. 7th edition, 2014.

Kestenbaum M, Waters C. Magnetic Resonance Imaging and Dopamine Transporter Single Photon Emission Tomography in Parkinson’s Disease—When Should We Use Them? US Neurology,2014;10(2):90–1

Marek K1, Seibyl J, Eberly S, Oakes D, Shoulson I, Lang AE, Hyson C, Jennings D; For The Parkinson Study Group PRECEPT Investigators. Longitudinal follow-up of SWEDD subjects in the PRECEPT Study Neurology 2014;82:1791-1797.

Alcalay RN, Dinur T, Quinn T, Sakanaka K, Levy OA, Waters C, Fahn S, Dorovski T, Chung WK, Pauciulo M, Nichols W, Rana HQ, Balwani M, Bier L, Elstein D, Zimran A. Comparison of Parkinson Risk in Ashkenazi Jewish Gaucher Patients and GBA Heterozygotes 2014 Jun;71(6):752-7. doi: 10.1001/jamaneurol.2014.313.

Waters C. The development of the rotigotine transdermal patch: a historical perspective. Neurol Clin. 2013 Aug;31(3 Suppl):S37-50. doi: 10.1016/j.ncl.2013.04.012. Epub 2013 Jun 14.

Arkadir D, Greene PE, Waters CH, Moskowitz CB, Sharp ME. Applause sign in clinically overlapping diseases: a case of TDP-43 proteinopathy. Park Relat Disord2013 Aug;19(8):774-5. doi: 10.1016/j.parkreldis.2013.04.016. Epub 2013 May 13.

Alcalay RN, Caccappolo E , Mejia-Santana H , Tang M –X , Rosado L , Orbe Reilly M,Ruiz D , Louis ED , Comella C ,  Nance M , Bressman S , Scott WK , Tanner C , Mickel S , Waters C  et al,  Cognitive and motor function in long duration PARKIN PD. Arch Neurol 2013 Nov 4. doi: 10.1001

Alcalay RN, Mirelman A, Saunders-Pullman R, Tang MX, Mejia Santana H, Raymond D, Roos E, Orbe-Reilly M, Gurevich T, Bar Shira A, Gana Weisz M, Yasinovsky K, Zalis M, Thaler A, Deik A, Barrett MJ, Cabassa J, Groves M, Hunt AL, Lubarr N, San Luciano M, Miravite J, Palmese C, Sachdev R, Sarva H, Severt L, Shanker V, Swan MC, Soto-Valencia J, Johannes B, Ortega R, Fahn S, Cote L, Waters C et al. Parkinson Disease Phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations. Mov Disord. 10/15/2013.

Hauser RA, Hsu A, Kell S, et al. Extended-release carbidopa – levodopa (IPX066) compared with immediate – release carbidopa – levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomized, double-blind trial. The Lancet Neurology 2013;12: 346-356.

Liu X, Cheng R, Ye X, Verbitsky M, Kisselev S, Mejia-Santana H, Louis ED, Cote LJ, Andrews H, Waters C, Ford B, Fahn S, Marder K, Lee JH and Clark LN. Increased rate of Sporadic and Recurrent Rare Genic Copy Number Variants in Parkinson's Disease among Ashkenazi Jews. Molecular Genetics and Genomic Medicine. 2013. 1(3), 142-154.

Sakanaka K, Waters CH, Levy OA, Louis ED, Chung WK, Marder KS, Alcalay RN.  Knowledge of and interest in genetic results among Parkinson disease patients and caregivers. J Genet Counsel 2013. Doi 10.1007/s10897-013-9618-y

Waters C, Smolowitz J: Sexual Dysfunction. In: Parkinson's disease: second edition, CRC press, Pfeiffer R,  Wszolek Z, Ebadi M,Eds, 2013, pp 343-352.

Waters CH and Smolowitz J:  Impaired Sexual Function. In: Parkinson’s Disease and Nonmotor Dysfunction. Pfeiffer RF, Bodis-Wollner I (eds) Humana Press  (Springer Science, New York) 2013, pp 173-187.

Waters C, The Development of the Rotigotine Transdermal Patch: A  Historical Perspective Neurologic Clinics 2013 Aug;31(3 Suppl):S37-50. doi: 10.1016/j.ncl.2013.04.012. Epub 2013 Jun 14.

Wright, B Waters CH. Continuous Dopaminergic Delivery to Minimize Motor Complications in Parkinson’s Disease. Expert reviews of Neurotherapeutics2013 Jun;13(6):71929. doi: 10.1586/ern.13.47.


Neurological Institute of New York

710 West 168th Street
New York, NY 10032

Phone: (212) 305-1303

Fax: (212) 305-1304

Get Directions

ColumbiaDoctors Tarrytown

155 White Plains Road
Suite W100
Tarrytown, NY 10591

Phone: (914) 366-4200

Get Directions

Albert B. and Judith L. Glickman Professor of Neurology at CUMC